PGLYRP1

Across TCGA pan-cancer cohorts, PGLYRP1 RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of PGLYRP1’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where PGLYRP1 RNA is repressed in tumor relative to normal tissue. In most cancer types PGLYRP1 is over-expressed in tumor, although a few such as LIHC and LUSC show the opposite, repressed pattern.

LIHC, LUSC, and BRCA are the cancer types where PGLYRP1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PGLYRP1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Male	II,III,IV	−0.390	<.001	8	view →
LUSC	All	II,III,IV	−1.213	<.001	5	view →
BRCA	All	III,IV	−0.171	.010	5	view →
KIRC	All	All	+0.146	.011	5	view →
LUAD	Male	All	−0.936	<.001	4	view →
KICH	All	All	−0.259	.014	4	view →
THCA	Male	All	−0.205	.005	3	view →
CHOL	All	II,III,IV	−0.130	.002	2	view →
KIRP	Male	All	−0.177	.029	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

PGLYRP1–LIHC

Open the LIHC breakdown →